← Leaderboards
Gavin Ha
Fred Hutchinson Cancer Research Center
$4,673,787
Attributed
$5,551,397
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,551,397 · 4
By mechanism
DP2$2,812,871 · 1
R01$1,755,220 · 1
K22$568,296 · 1
R21$415,010 · 1
Top collaborators
- Peter S Nelson3 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Joshi James Alumkal$6,560,072
- Colm M Morrissey$3,479,548
- Robert Neil Eisenman$37,903,199
- Viswam Siva Nair$993,546
- Mads Daugaard$838,161
Others in their field
Other Emerging Leaders on “Cell Free Dna”
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Robert Nicol · Broad Institute, Inc.$7,498,771
- Gordon M Ringold · Quadriga Biosciences, Inc.$6,041,839
- Muhammed Murtaza · Translational Genomics Research Inst$5,522,566
- Marlena Habal · Columbia University Health Sciences$5,428,816
- Crystal Mackall · Children'S Hosp Of Philadelphia$4,614,281
Research focus
Cell Free DnaTumorResistanceBloodSamplingMalignant NeoplasmsMolecularNeoplastic CellBiopsyTherapy ResistantPlasmaMalignant Neoplasm Of ProstateLiquid BiopsyDna Sequence AlterationOncogenesTreatment ResponseCessation Of LifeCancer PatientGenomicsInnovationPatient Derived Xenograft ModelClassificationGenomePhenotype
Grant awards (12)
Translating the tumor regulome from cell-free DNA for precision oncology$1,056,000
DP2 · FY2025 · CA · contact PI
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes$592,110
R01 · FY2025 · CA · contact PI
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes$566,644
R01 · FY2024 · CA · contact PI
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes$596,466
R01 · FY2023 · CA · contact PI
Translating the tumor regulome from cell-free DNA for precision oncology$214,790
DP2 · FY2023 · CA · contact PI
Translating the tumor regulome from cell-free DNA for precision oncology$1,542,081
DP2 · FY2022 · CA · contact PI
Identifying driver non-coding alterations in metastatic prostate cancer from tumor and cell-free DNA$189,432
K22 · FY2022 · CA · contact PI
Predicting transcriptional signatures and tumor subtypes from circulating tumor DNA$168,170
R21 · FY2022 · CA · contact PI
Predicting transcriptional signatures and tumor subtypes from circulating tumor DNA$201,895
R21 · FY2021 · CA · contact PI
Identifying driver non-coding alterations in metastatic prostate cancer from tumor and cell-free DNA$189,432
K22 · FY2021 · CA · contact PI
Predicting transcriptional signatures and tumor subtypes from circulating tumor DNA$44,945
R21 · FY2021 · CA · contact PI
Identifying driver non-coding alterations in metastatic prostate cancer from tumor and cell-free DNA$189,432
K22 · FY2020 · CA · contact PI